tiprankstipranks
Trending News
More News >
Biotest (0N6Z) (DE:BIO)
:BIO

Biotest (BIO) AI Stock Analysis

Compare
4 Followers

Top Page

DE

Biotest

(LSE:BIO)

Rating:53Neutral
Price Target:
€43.00
▲(4.37%Upside)
Biotest's overall stock score is driven primarily by its stable financial position and improved cash flows, despite operational challenges affecting profitability. The technical outlook is neutral with limited momentum, and the valuation remains a significant concern due to the negative P/E ratio. The high dividend yield provides some support but is overshadowed by the valuation risks.

Biotest (BIO) vs. iShares MSCI Germany ETF (EWG)

Biotest Business Overview & Revenue Model

Company DescriptionBiotest AG is a Germany-based biotechnology company specializing in the development and production of plasma protein therapies and biotherapeutic drugs. The company operates primarily in the healthcare sector, focusing on products for clinical immunology, hematology, and intensive care medicine. Biotest's core products include immunoglobulins, clotting factors, and albumin solutions, which are used in treating various life-threatening diseases and conditions.
How the Company Makes MoneyBiotest generates revenue through the manufacturing and sale of plasma protein products and biotherapeutic drugs. The company's key revenue streams include sales of immunoglobulins, which are essential for patients with immune deficiencies; clotting factors used for treating hemophilia and other bleeding disorders; and albumin solutions used in intensive care settings. Biotest also engages in research and development activities aimed at expanding its product portfolio and improving existing therapies. Strategic partnerships and collaborations with other pharmaceutical and biotechnology firms can also contribute to its earnings by facilitating market expansion and distribution of its products.

Biotest Financial Statement Overview

Summary
Biotest shows balanced financial performance with a stable balance sheet and improved cash flows. However, there are challenges in maintaining consistent profitability due to operational inefficiencies.
Income Statement
65
Positive
Biotest's income statement shows a mixed performance. Gross Profit Margin improved to 30.82% in the latest year, coupled with a positive Net Profit Margin of 3.63%, indicating moderate profitability. However, the company experienced a significant drop in Gross Profit from the previous year, suggesting volatility in profit generation. Revenue growth from 2023 to 2024 was 6.08%, which is positive but marked by a decline in EBIT and EBITDA margins, indicating rising operational costs or inefficiencies.
Balance Sheet
72
Positive
The balance sheet of Biotest indicates a stable financial position. The Debt-to-Equity Ratio stands at 1.13, reflecting a balanced capital structure. Return on Equity is modest at 4.97%, showing moderate returns to equity holders. The Equity Ratio of 37.00% suggests a strong equity base relative to total assets, enhancing financial stability. However, the increase in total debt over time could pose potential risks if not managed well.
Cash Flow
70
Positive
Biotest's cash flow statements reveal stable cash flow management. Operating Cash Flow to Net Income Ratio is 2.31, indicating strong cash generation relative to net income. Free Cash Flow improved significantly to a positive $32.2 million in 2024 from a negative position in the prior year, suggesting robust cash flow improvement. However, the fluctuation in free cash flow growth over the years denotes potential instability in cash generation capability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue726.20M684.60M516.10M515.60M484.20M
Gross Profit223.80M280.30M124.90M80.70M130.10M
EBITDA120.40M179.00M28.30M-17.70M16.00M
Net Income26.40M127.00M-31.60M-63.30M-31.40M
Balance Sheet
Total Assets1.43B1.41B1.20B1.10B1.13B
Cash, Cash Equivalents and Short-Term Investments119.50M118.50M136.60M117.50M89.20M
Total Debt597.20M689.80M574.30M496.30M469.10M
Total Liabilities903.30M912.00M831.90M723.80M689.70M
Stockholders Equity530.70M498.90M371.10M380.40M441.60M
Cash Flow
Free Cash Flow32.20M-36.10M-69.80M15.70M-43.70M
Operating Cash Flow60.90M-2.70M-40.50M33.90M-16.70M
Investing Cash Flow-25.70M1.30M-37.00M-23.40M-14.60M
Financing Cash Flow-35.40M-6.80M89.60M22.60M42.00M

Biotest Technical Analysis

Technical Analysis Sentiment
Positive
Last Price41.20
Price Trends
50DMA
42.14
Negative
100DMA
41.83
Positive
200DMA
41.66
Positive
Market Momentum
MACD
0.06
Negative
RSI
50.19
Neutral
STOCH
10.14
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Positive. The current price of 41.2 is below the 20-day moving average (MA) of 41.40, below the 50-day MA of 42.14, and below the 200-day MA of 41.66, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 50.19 is Neutral, neither overbought nor oversold. The STOCH value of 10.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BIO.

Biotest Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
DEEUZ
75
Outperform
€1.38B40.2117.48%0.65%15.89%14.62%
DEEUZ
75
Outperform
€1.38B40.2117.48%0.65%15.89%14.62%
64
Neutral
€6.40B20.05-1.17%2.13%0.06%-43.17%
62
Neutral
€322.90M21.462.99%5.62%-21.87%
62
Neutral
€322.90M21.462.99%5.62%-21.87%
DEBIO
53
Neutral
€1.40B64.15-4.72%0.10%-18.82%-113.85%
DEFYB
51
Neutral
€514.03M5.89-26.06%-10.32%-250.76%
DEFYB
51
Neutral
€514.03M5.89-26.06%-10.32%-250.76%
DEEVT
46
Neutral
€1.28B-20.51%1.50%-127.76%
DEEVT
46
Neutral
€1.28B-20.51%1.50%-127.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:BIO
Biotest
42.00
0.40
0.96%
DE:EVT
Evotec
7.20
-2.18
-23.28%
DE:EVT
Evotec
7.20
-2.18
-23.28%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
66.50
26.97
68.23%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
66.50
26.97
68.23%
DE:ILM1
Medios AG
13.00
-2.90
-18.24%
DE:ILM1
Medios AG
13.00
-2.90
-18.24%
DE:FYB
Formycon AG
28.85
-25.45
-46.87%
DE:FYB
Formycon AG
28.85
-25.45
-46.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025